Oncology Patient-focused manufacturing models for personalised therap... In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jason Bock, co-founder and CEO of CTMC, a first-of-its-kind cell therapy engine.
R&D Defining, building, and implementing the next wave of biopha... In a new podcast, pharmaphorum speaks with two PharmaLex experts about navigating complex R&D processes to unleash the next wave of biopharma.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.